moonlake immunotherapeutics - MLTX
MLTX
Close Chg Chg %
16.52 0.84 5.08%
Closed Market
17.36
+0.84 (5.08%)
Volume: 1.69M
Last Updated:
Apr 2, 2026, 4:00 PM EDT
Company Overview: moonlake immunotherapeutics - MLTX
MLTX Key Data
| Open $16.28 | Day Range 16.02 - 17.53 |
| 52 Week Range 5.95 - 62.75 | Market Cap $1.25B |
| Shares Outstanding 71.73M | Public Float 62.91M |
| Beta 1.19 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$3.53 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.11M |
MLTX Performance
| 1 Week | 0.23% | ||
| 1 Month | -4.35% | ||
| 3 Months | 45.27% | ||
| 1 Year | -53.35% | ||
| 5 Years | 69.20% |
MLTX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
17
Full Ratings ➔
About moonlake immunotherapeutics - MLTX
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
MLTX At a Glance
MoonLake Immunotherapeutics
Dorfstrasse 29
Zug, Zug 6300
| Phone | 41-41-510-80-22 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -227,318,000.00 | |
| Sector | Health Technology | Employees | 130 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MLTX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 3.09 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.194 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.142 |
MLTX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,748,600.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MLTX Liquidity
| Current Ratio | 9.272 |
| Quick Ratio | 9.272 |
| Cash Ratio | 8.663 |
MLTX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -50.383 |
| Return on Equity | -60.513 |
| Return on Total Capital | -59.791 |
| Return on Invested Capital | -54.958 |
MLTX Capital Structure
| Total Debt to Total Equity | 24.865 |
| Total Debt to Total Capital | 19.913 |
| Total Debt to Total Assets | 17.837 |
| Long-Term Debt to Equity | 24.459 |
| Long-Term Debt to Total Capital | 19.589 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Moonlake Immunotherapeutics - MLTX
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | - | - | - |
Sales Growth
| - | - | - | - | - |
Cost of Goods Sold (COGS) incl D&A
| 12.36K | 13.16K | 1.38M | 2.62M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 12.36K | 13.16K | 1.38M | 2.62M | |
Depreciation
| 12.36K | 13.16K | 1.38M | 2.62M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +6.47% | +10,423.86% | +88.92% | |
Gross Income
| (12.36K) | (13.16K) | (1.38M) | (2.62M) | |
Gross Income Growth
| - | -6.47% | -10,423.86% | -88.92% | |
Gross Profit Margin
| - | - | - | - | - |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 65.05M | 54.11M | 141.71M | 242.22M | |
Research & Development
| 42.04M | 31.79M | 111.39M | 200.25M | |
Other SG&A
| 23.01M | 22.32M | 30.32M | 41.97M | |
SGA Growth
| +1,323.29% | -16.82% | +161.89% | +70.93% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (65.06M) | (54.12M) | (143.09M) | (244.83M) | |
Non Operating Income/Expense
| 591.73K | 10.14M | 22.13M | 22.37M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 7.25M | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | 7.25M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (64.47M) | (43.98M) | (120.96M) | (229.71M) | |
Pretax Income Growth
| -1,319.21% | +31.77% | -175.01% | -89.90% | |
Pretax Margin
| - | - | - | - | - |
Income Tax
| 36.37K | 94.39K | 282.20K | 611.00K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (64.51M) | (44.08M) | (121.24M) | (230.32M) | |
Minority Interest Expense
| (14.53M) | (8.07M) | (2.31M) | (3.00M) | |
Net Income
| (49.97M) | (36.01M) | (118.94M) | (227.32M) | |
Net Income Growth
| -1,000.09% | +27.95% | -230.31% | -91.13% | |
Net Margin Growth
| - | - | - | - | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (49.97M) | (36.01M) | (118.94M) | (227.32M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (49.97M) | (36.01M) | (118.94M) | (227.32M) | |
EPS (Basic)
| -1.702 | -0.733 | -1.8918 | -3.5263 | |
EPS (Basic) Growth
| -454.76% | +56.93% | -158.09% | -86.40% | |
Basic Shares Outstanding
| 29.36M | 49.12M | 62.87M | 64.46M | |
EPS (Diluted)
| -1.702 | -0.733 | -1.8918 | -3.5263 | |
EPS (Diluted) Growth
| -454.76% | +56.93% | -158.09% | -86.40% | |
Diluted Shares Outstanding
| 29.36M | 49.12M | 62.87M | 64.46M | |
EBITDA
| (65.05M) | (54.11M) | (141.71M) | (242.22M) | |
EBITDA Growth
| -1,323.29% | +16.82% | -161.89% | -70.93% | |
EBITDA Margin
| - | - | - | - | - |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 29.60 | |
| Number of Ratings | 17 | Current Quarters Estimate | -0.903 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -3.617 | |
| Last Quarter’s Earnings | -0.897 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -3.529 | Next Fiscal Year Estimate | -3.639 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 12 | 12 | 14 | 15 |
| Mean Estimate | -0.90 | -0.92 | -3.62 | -3.64 |
| High Estimates | -0.77 | -0.68 | -2.66 | -2.60 |
| Low Estimate | -1.04 | -1.08 | -4.32 | -5.21 |
| Coefficient of Variance | -9.99 | -13.77 | -14.31 | -19.48 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 13 | 13 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 2 | 2 | 3 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 2 | 2 | 3 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Moonlake Immunotherapeutics - MLTX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Moonlake Immunotherapeutics - MLTX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jan 12, 2026 | Kristian Reich Chief Scientific Officer | 520,342 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 12, 2026 | Jorge Santos da Silva Chief Executive Officer; Director | 520,342 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jan 12, 2026 | Matthias Bodenstedt Chief Financial Officer | 1,276,305 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 23, 2025 | Kristian Reich Chief Scientific Officer | N/A | Conversion of derivative security | 0.00 |
| Dec 23, 2025 | Jorge Santos da Silva Chief Executive Officer; Director | N/A | Conversion of derivative security | 0.00 |
| Dec 23, 2025 | Matthias Bodenstedt Chief Financial Officer | N/A | Conversion of derivative security | 0.00 |
| Oct 3, 2025 | Cormorant Asset Management LP | 8,423,403 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $9.38 per share | 79,011,520.14 |
| Oct 3, 2025 | Cormorant Asset Management LP | 8,190,943 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.4 per share | 68,803,921.20 |
| Oct 3, 2025 | Cormorant Asset Management LP | 4,800,000 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.58 per share | 36,384,000.00 |
| Oct 3, 2025 | Cormorant Asset Management LP | 2,000,000 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.61 per share | 13,220,000.00 |
| Oct 3, 2025 | Cormorant Asset Management LP | 1,994,173 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $6.96 per share | 13,879,444.08 |
| Jul 8, 2025 | Catherine Moukheibir Director | 23,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 8, 2025 | Catherine Moukheibir Director | N/A | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $48.79 per share | 0.00 |
| Jul 8, 2025 | Catherine Moukheibir Director | 21,500 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |